Home

Search Abstracts

Browse Sessions

Program Committee

Conference Webcasts

Contact Us

---

Session 128   Poster Abstracts Treatment in Pregnant Women and Children: Pharmacokinetics Wednesday, 1:30 - 3:30 pm Poster Hall

932	Steady State Nevirapine Pharmacokinetics during Second and Third Trimester Pregnancy and Postpartum: PACTG 1022 F Aweeka*1, P Lizak1, L Frenkel2, S Au1, H Watts3, J McNamara3, L Stevens4, J Hitti2, and PACTG 1022 Study Team 1Univ. of California, San Francisco, USA; 2Univ. of Washington, Seattle, USA; 3NIH, DHHS, Bethesda, MD, USA; and 4Frontier Sci. and Technology Res. Fndn., Buffalo, NY, USA
933	Population Pharmacokinetics of Low-dose Nevirapine for Prevention of Breast Milk HIV Transmission in Infants from Birth through 6 Months of Age M Mirochnick*1, E Capparelli2, Suzette Blanchard3, A K Shetty4, H M Coovadia5, J Wells6, A Dilraj7, P Mateta6, L Mofenson8, S Adeniyi Jones9, and HPTN 023 Protocol Team 1Boston Univ. Sch. of Med., MA, USA; 2Univ. of California, San Diego, Sch. of Med., USA; 3Statistical and Data Analysis Ctr. (SDAC), Harvard Sch. of Publ. Hlth., Boston, MA, USA; 4Stanford Univ. Sch. of Med., Palo Alto, CA, USA; 5Univ. of Natal, Durban, South Africa; 6Zimbabwe AIDS Prevention Project and Univ. of Zimbabwe, Harare; 7Med. Res. Council South Africa, Durban, South Africa; 8NICHD, NIH, DHHS, Bethesda, MD, USA; and 9NIAID, NIH, DHHS, Bethesda, MD, USA
934	Pharmacokinetics of Once Daily vs Twice Daily Lamivudine and Abacavir in HIV-1-infected Children: PENTA 13 A Bergshoeff*1,2, D Burger1,2, L Farrelly3, J Flynn4, M LeProvost5, V Novelli4, H Lyall5, D Gibb3, and PENTA-13 Study Group 1Univ. Med. Ctr. Nijmegen, The Netherlands; 2Nijmegen Univ., Ctr. for Infectious Diseases, The Netherlands; 3MRC Clin. Trials Unit, London, UK; 4Great Ormond Street Hosp. for Sick Children, London, UK; and 5Infectious Diseases Unit, Family Clinic, St. Mary’s Hosp., London, UK
935	Pharmacokinetics of Tenofovir DF Oral Suspension in HIV-1-infected Children between 2 and 8 Years of Age B P Kearney*1, J Abadi2, M Rosenberg2, J Dobroszycki2, M Nguyen1, K Yale1, J Flaherty1, and A Wiznia2 1Gilead Sci., Inc., Foster City, CA, USA and 2Jacobi Med. Ctr., Bronx, NY, USA
936	Extended Follow-up and Pharmacokinetics for Once Daily Emtricitabine, Didanosine, and Efavirenz for Antiretroviral Naïve Children and Adolescents R McKinney*1, J Rodman2, M Rathore3, C Hu4, P Flynn2, M Hughes4, R Dickover5, A Weinberg6, M R Blum7, D Sahner8, S Jankelevich9, L Serchuck10, B Ortiz11, P Tran9, and Pediatric AIDS Clinical Trials Group 1Duke Univ., Durham, NC, USA; 2St. Jude Children's Res. Hosp., Memphis, TN, USA; 3Univ. of Florida HSC, Jacksonville, USA; 4Statistical and Data Analysis Ctr. (SDAC), Harvard Sch. of Publ. Hlth., Boston, MA, USA; 5Univ. of California, Los Angeles, Sch. of Med., USA; 6Univ. of Colorado Hlth. Sci. Ctr., Denver, USA; 7Gilead Sci., Inc., Durham, NC, USA; 8Bristol-Myers Squibb Co., Wallingford CT, USA; 9NIAID, NIH, DHHS, Bethesda, MD, USA; 10NCI HIV/AIDS Branch, NIH, DHHS, Bethesda, MD, USA; and 11PACTG Operations Ctr., Silver Spring, MD, USA
937	Pharmacokinetics and Safety of Lopinavir/ritonavir Doses Greater than 300 mg/m2/ in Children and Adolescents with HIV Infection P Havens*1,2, M Frank1, B Cuene2, V Decker2, R Kohler2, A Wolfe2, and M Yenter2 1Med. Coll. of Wisconsin, Milwaukee, WI, USA and 2Children's Hosp. of Wisconsin, Milwaukee, USA